anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:The titled remedy, containing a 3-phenyl-4H-1-benzopyran-4-one derivative as an active constituent, and capable of exhibiting inhibitory action on absorption of bones by direct action on the bones. CONSTITUTION:A remedy for osteoporosis containing a compound expressed by formula I (R<1> is H or OH; R<2> or R<3> is H or lower alkyl; Y is carboxyl or a group convertible into the carboxyl) as an active constituent. The compound expressed by formula I is obtained by reacting a hydroxy compound expressed by formula II with an alpha-halogenocarboxylic acid expressed by formula III (X is halogen) or a derivative thereof, and if necessary hydrolyzing the reaction product. The dose thereof is 10-500mg/day/man, and the dosage form thereof is a tablet, powder, granule, capsule, solution, etc. for oral administration and 1- 100mg/time injection, etc. for parenteral administration.
Contact volunteers are those volunteers whose partner/spouse is a Challenge volunteer. Investigators will monitor Contact volunteers to collect information about transmission. A 3 day course of Azithromycin will be administered on week 6 if colonised.
INTRODUCTION: This study explored vocabulary development and lexical composition in young typically developing (TD) Kuwaiti children and late talkers (LT) using the Kuwaiti Arabic Communicative Development Inventory-Words and Sentences (KACDI-WS) Abdalla et al., 2016). The sample included 161 children aged 20 to 37 months: 127 TD and 34 children who were late talkers (LT group). The late talkers were first identified based on a background questionnaire answered by the parents. All the caregivers completed a 698-item web-based KACDI expressive vocabulary inventory by selecting non-imitative words that their children produced.
RESULTS: Lexical size and composition (nouns, predicates, and closed-class words) were analyzed. Across the TD age groups (20-26, 27-31, 32-37 months), a significant age effect for vocabulary size and composition was found in favor of the older groups. Nouns were more prevalent than predicates or closed-class words in within-group comparisons. The vocabulary size of the TD (M= 263.8) was significantly larger than that of the LT group (M= 69.2). The development of their lexical composition followed a similar pattern.
CONCLUSIONS: The results suggested that the KACDI parent report instrument has the potential for measuring vocabulary development in TD children and could serve as an initial screening tool to identify late talkers.
The present invention relates to bacillus natto NLSSe preserved in a general microbiology center of China Microscobial Preservation Management Committee on 8 March 2002, and the preservation number of the bacillus natto NLSSe is CGMCCNO. 0724. The gram-positive bacillus natto without acid-fast bacilli is straight or approximately straight, and the size of the bacillus natto is (0.6 to 0.8) *(1.5 to 2.0) um. The bacillus natto which is aerobic comprises a spore growing mesially without swelling, and the number of the spore is not more than one in a sporange cell; a chemical constituent of the cell wall comprises meson-diaminopimelic acid and glycine. The bacillus natto without characteristic saccharum can move with peripheral flagella. The bacillus natto grows well on Danzi peptone Chashi agar, Santas agar, leached beef juice agar, bean flour agar or glucose yeast extract agar which are natural organic culture media. A thicker bacillus membrane is formed by utilizing a culture medium of bean cake flour; a bacillus colony is in the color of milk fat, and the edge of the bacillus colony is smooth. The bacillus natto can be cultured in a culture medium containing a nitrogen source to obtain a cultured substance containing natto kinase which is a thrombus dissolvable substance, and a powdery substance which can be extracted from the cultured substance can be used for preparing a thrombus dissolvable health-care food or a health-care food additive.
BACKGROUND: The neonatal mortality rate is a main indicator of the health and development of a country. Having insight into the cause of neonatal deaths may be the first step to reducing it. This paper depicts the cause of newborn deaths in Iran.
METHODS: This cross-sectional study was performed on data from the national Iranian Maternal And Neonatal network to investigate all neonatal deaths in the country during the year 2019. The cause of death data were reported according to categories of birth weight, gestational age (GA), death time and place.
RESULTS: The main causes of the 9959 neonatal deaths during the study period were respiratory distress syndrome (RDS) (37%), malformation (21%), prematurity of <26 weeks (20%), others (12%), asphyxia (7%) and infection (3%). The major causes of neonatal mortality in delivery rooms were prematurity of <26 weeks and in the inpatient wards the RDS. By increasing the GA and birth weight towards term babies, the rate of RDS gets lower, while that of malformation gets higher.
CONCLUSIONS: RDS was the main cause of neonatal mortality in Iran which is seen mainly in preterm babies. Prematurity of <26 weeks was another main cause. Thus, suggestions include reducing prematurity by preconception and pregnancy care and, on the other hand, improving the care of preterm infants in delivery rooms and inpatient wards.
This is a first-in-human (FIH), Phase 1 randomized, placebo-controlled, single and multiple ascending dose trial of KT-474 that will characterize the safety, PK and PD of orally administered KT-474 after a single dose (Part A) and after repeated dosing first in healthy adult volunteers (Part B) and then in patients with AD or HS (Part C). Initially, a dose range of KT-474 in single ascending dose (SAD) escalation cohorts will be explored in healthy subjects. Up to five single dose cohorts of healthy subjects is also planned to understand food effects (FE) on the PK of KT-474. Enrollment of healthy subjects into 2-week multiple ascending dose (MAD) escalation cohorts will be initiated once sufficient safety and PK data from multiple SAD cohorts are available to inform the safe starting dose for the 2-week MAD portion of the study. After the MAD portion in healthy subjects is completed, the safety, PK, and PD of a dose of KT-474 that was found to be safe in healthy subjects when administered for 2 weeks will then be evaluated in AD or HS subjects for 28 days of dosing. Separately, additional multiple dose cohorts evaluating once every other day and/or twice weekly dosing schedules at or below previously evaluated dose levels in healthy volunteers may be initiated.
The present invention discloses a dropping pill for treating gynecology and a preparation method thereof. The dropping pill of the present invention is prepared by adding Yunnan and Guangxi blumea dried ointment powder into dissolved base materials, uniformly stirring the dried ointment powder, dropping liquid medicine into cooling liquid, taking dropping pills by sucking the cooling liquid, and drying the dropping pills. The medicine of the present invention has the advantages of simple and specific composition, advanced technology and easy control of quality. Prepared dropping pills can increase the application people. The dropping pill has the advantages of high technology, rapid curative effect, small volume, little dosage administration, convenient administration by patients, good mouth feel and high stability. The present invention has the advantages of reasonable design, convenient administration and portability, and has unique curative effects on gynecology haemorrhage pathological symptoms.
(What can I expect from Refissa?)

Refissa is a serious medication that may help treat but will not “cure” fine wrinkles, spotty skin discoloration, and rough feeling skin.

Studies show that after 24 weeks, about 30% of the people who used Tretinoin Cream, USP (Emollient) 0.05% for fine wrinkles or spotty discoloration had moderate improvement, another 35% had minimal improvement and 35% had no improvement. About 16% of the people who used Tretinoin Cream, USP (Emollient) 0.05% for rough skin had moderate improvement, 35% had minimal improvement, and 49% had no improvement. There is no evidence that Refissa treats coarse skin, deep wrinkles, yellowing skin, or other skin care problems.

Refissa should be used as part of a broad skin care program. This program should include avoiding direct sunlight (by using protective clothing and sunscreens with a minimum SPF of 15) and using other moisturizing facial creams that do not contain tretinoin. Many people can achieve desired effects by using this program without using Refissa. You should not use Refissa until you have tried a broad skin treatment program without Refissa.

When you use Refissa, improvement in fine wrinkling, spotty skin discoloration and rough skin is not immediate and occurs gradually over time. Generally, you may notice some effects in 3 to 4 months. The effects are usually most noticeable at about 6 months with little additional improvement after that time. If Refissa is stopped, the improvement will gradually diminish.

The safety of using Refissa daily for more than 48 weeks has not been established.
This study aimed to investigate the relationship between the systemic immune inflammation index (SII), platelet-to-lymphocyte ratio (PLR), neutrophil-to-lymphocyte ratio (NLR), and disease activity and functional status in patients with ankylosing spondylitis (AS). A cross-sectional clinical study was conducted, and a total of 90 patients diagnosed with AS according to the Modified New York Criteria, aged between 18 and 65, who presented to our outpatient clinics were included in the study. Demographic data, disease duration, age at symptom onset, and laboratory parameters, including platelet, neutrophil, basophil, eosinophil, lymphocyte counts, mean platelet volume (MPV), red blood cell distribution width (RDW), C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR), were recorded. NLR and PLR values were calculated. The Systemic Immune Inflammation Index (SII) was calculated by dividing the product of neutrophil and platelet counts by the lymphocyte count. We investigated all of these parameters and disease activity scores. Disease activity was assessed with the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), spinal mobility with the Bath Ankylosing Spondylitis Metrology Index (BASMI), and functional status with the Bath Ankylosing Spondylitis Functional Index (BASFI). In addition, during the routine follow-ups of patients, requested blood tests were examined, and platelet, neutrophil, basophil, eosinophil, lymphocyte counts, mean platelet volume (MPV), RDW (red blood distribution width), CRP, and ESR values will be recorded. Neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), and systemic immune inflammation index (SII) were calculated
Malignant solid tumors including lung and liver cancers are the most common malignancy worldwide, and their mortality rates are very high. China has a huge population base, with about 4,000,000 new cases each year. More than 60% of the solid tumors in China are diagnosed at mid-to-late stage and have lost the chance of surgery. Recently a lot of therapeutic strategies have been developed and applied to clinic including targeted therapy and immunotherapy, but the overall efficiency is still low. It is difficult to be widely used in patients with advanced solid cancers, and more alternative therapies are urgently needed.

Antibodies against PD1, PDL1 and CTLA4 are representative drugs for the check-points inhibitory agents, and their clinical indications have been approved in various types of tumors, including advanced melanoma, non-small cell lung cancer, renal cell carcinoma, and classical Hodgkin's lymphoma and late recurrent head and neck squamous cell carcinoma patients, et al. Those drugs are regularly systemically administrated by vein infusion, however, local delivery of those drugs via interventional radiology technique including trans-artery or intra-tumor injection may increase the local drug concentration in the tumor, improve the efficacy, and reduce systemic adverse reactions, through so called "first pass effect" of drug on target organs. To the investigator's knowledge, no studies have been developed on the efficacy and survival benefit of localized delivery of checkpoint inhibitors for treatment of cancer patients. This phase II-III clinical trial was designed to compare the effects of Pembrolizumab, Tecentriq, et al and/or ipilimumab plus chemotherapeutic drug such as doxorubicin on the survival benefit of patients with advanced solid cancers, including ORR, DCR, median survival time, and safety.
A study by Lambert et. al. (2012) was able to objectively identify patients with NAIR by intranasal capsaicin challenge followed by assessment with optical rhinometry. Studies have shown that capsaicin therapy can improve symptoms of patients historically identified with NAIR via visual analog scale (VAS) rating of symptoms and symptom surveys; however, there has been no study evaluating the capsaicin therapy on patients objectively identified as NAIR patients.

Multiple studies have demonstrated that intranasal capsaicin can improve nasal symptoms of NAIR patients. Regarding the usage of capsaicin, there is a product on the market: Sinus Buster which has capsaicin as the active ingredient. Numerous research papers have evaluated the efficacy and safety of Sinus Buster for the treatment of congestion in non-allergic rhinitis patients. However, the diagnosis of NAIR in these previous studies was based primarily on history. In addition, the primary outcome in these studies was symptomatic without any objective evaluation. The goal of this study will be two-fold: with patients objectively identified as NAIR patients via the optical rhinometer, we will re-evaluate the therapeutic action of intranasal capsaicin on the management of rhinitic symptoms. We expect that the patients will show significant improvement in their symptoms. We will then use optical rhinometry as a means to objectively monitor changes in symptoms in NAIR patients. We expect that post treatment, patients will no longer have the positive response previously seen on intranasal capsaicin challenge before receiving treatment. We hope to be able to establish optical rhinometry as an objective measurement of symptom improvement for NAIR symptoms, along with the subjective patient surveys.
The present invention relates to a Chinese medicament inhaled by patients for curing cold, which is mainly prepared from alcohol, peppermint, flos caryophyllata, camphor, encalyptus leaf, blinding tree, para-thymoquinone and baras camphor. The Chinese medicament inhaled by patients for curing cold is prepared by extraction and refining. Commonly, the symptoms of patients with cold are alleviated right away as soon as the patients inhale the medicament. After inhaling for 2 to 3 days, the patients can be basically recovered. The medicament has the advantages of no toxic or side effect to the human body, safe and convenient use and portability. Besides, the medicament also has the actions of refreshing oneself, restoring consciousness and eliminating fatigue.
Xanthan gum-based food thickeners have been reported to potentially interfere with tablet disintegration. Loxoprofen sodium (LOX) is widely used as an antipyretic analgesic and is expected to provide rapid pain relief. In this study, we aimed to investigate the impact of a xanthan gum-based food thickener on LOX tablet disintegration. We used four different brands each of medical and OTC-LOX tablets, each containing 60 mg of LOX as the sole active ingredient. Depending on the brand, tablet hardness varied between 50.1-96.6 N and was not associated with the disintegration time. Disintegration times for medical tablets not immersed in the food thickener were 536±215, 621±159, 348±22, 369±42 s and for OTC tablets, were 358±20, 336±13, 292±13, 172±27 s. Immersion in the food thickener for 15 min reduced medical tablet disintegration time to 177±46 and 233±150 s (the third and fourth brands were disintegrated during immersion), and that for OTC tablets to 77±40, 75±110, and 37±85 s (the fourth brand was disintegrated during immersion). Despite each tablet containing different pharmaceutical additives, no correlation was found between disintegration time and presence of superdisintegrants. The OTC tablet with a light anhydrous silicic acid coating exhibited the shortest disintegration time. Thus, the disintegration time of LOX tablets is accelerated when immersed in the xanthan gum-based food thickener, potentially leading to rapid pain relief for patients.
The invention belongs to the field of medicines, and particularly discloses application of cyclic diaryl heptanol. Use of diarylheptanol in the preparation of a formulation for inhibiting phosphorylation of PDGFR β and/or expression of the PDGFR β downstream pathway. Use of diarylheptanes alcohols in the preparation of a formulation for inhibiting smooth muscle phenotype switching. Use of diarylheptanes alcohols for the preparation of a medicament for the prevention or treatment of disorders induced by smooth muscle phenotype switching. Application of diaryl heptane alcohol in preparing medicine for preventing and treating cardiovascular diseases is provided. Use of diarylheptanol in the preparation of a formulation for inhibiting phosphorylation of PDGFR β and/or expression of the PDGFR β downstream pathway. Application of diaryl heptane alcohol in preparing preparation for inhibiting PDGF-BB induced cell proliferation is provided. An inhibitor of PDGFR β phosphorylation and/or PDGFR β downstream pathway expression, comprising at least one diarylheptanol. The invention discloses that diaryl heptanol has an inhibitory effect on PDGFR beta, so that the diaryl heptanol can inhibit smooth muscle phenotype switching, thereby preventing and/or treating restenosis after vascular injury.
The overarching goal of the HINT project is to develop an app that people affected by PCS can use on their own devices in a language of their choice (e.g. their native language) to increase their health and data literacy about PCS and to provide socially equitable access to PCS care. Multilingual avatars are used for independent data collection, as the embodiment of interaction systems offers advantages for health queries. The data collected during the survey and - if desired - data from wearables are combined with historical data from the participants, processed and visualized. This allows patients to communicate with their avatar as well as with medical staff about their illness and its progression without language barriers affecting treatment. The avatar can also inform patients about new research findings on PCS. To this end, the system's level of knowledge is constantly compared with the current state of science; new findings are prepared for the target group and added to the knowledge base. The project is aimed at all those affected by PCS, although the multilingualism and low-threshold health education are intended to appeal in particular to people who have previously had difficulty accessing adequate care. The project is aimed at all those affected by PCS, although the multilingualism and low-threshold health education are intended to appeal in particular to people who have previously had difficulty accessing adequate care. The participatory and iterative development of the system, which also involves medical staff, contributes to overarching issues relating to co-creation approaches in the healthcare sector.
The present invention relates to a gel-forming agent comprising a sulfa agent and a chitosan agent and having a powdered dosage form. In addition, the present invention provides a kit comprising the gel-forming agent of the present invention and a method comprising a step for applying the gel-forming agent of the present invention. According to the present invention, a gel-forming agent is provided that demonstrates a therapeutic effect that is more remarkable than that of conventional sulfa agents and chitosan agents alone, and more particularly, a gel-forming agent for protecting an exudative affected area and a gel-forming agent for treating a wound. Namely, by the applying the combination of a sulfa agent and a chitosan agent in the form of a powder, the pH of the affected area is maintained in a range that demonstrates a therapeutic effect, and antibacterial action of the sulfa agent is demonstrated. In addition, the moist environment at the affected area is suitably maintained for suitable granulation. In addition, as a result of being a powder, the use of a suitable dissipating container enables the gel-forming agent to be dispersed by a person performing treatment without making direct contact with the affected area.
The invention relates to a cerium oxide-loaded composite nano-drug, a soluble microneedle patch, a preparation method and application. The cerium oxide-loaded composite nano-drug comprises sodium lignin sulfonate, sodium copper chlorophyllin and cerium oxide. The invention also provides a preparation method of the cerium oxide-loaded composite nano-drug, which comprises the following steps: mixing the sodium lignin sulfonate aqueous solution and the sodium copper chlorophyllin aqueous solution, reacting for a first time, then adding the aqueous solution containing the cerium compound and the sodium hydroxide aqueous solution, and stirring for a second time to obtain the cerium oxide-carrying composite nano-drug. The invention also provides a soluble microneedle patch, which comprises the cerium oxide-loaded composite nano-drug. The invention also provides a preparation method of the soluble microneedle patch, which comprises the following steps: dispersing the cerium oxide-loaded composite nano-drug in a microneedle high polymer aqueous solution to obtain a high polymer mixed solution; casting the polymer mixed solution into a mould to obtain the soluble microneedle patch. The invention solves the problem of low absorption efficiency of sodium copper chlorophyllin.
The efficacy and safety of JATENZO was evaluated in 166 adult hypogonadal males in an open-label study of approximately 4 months duration (NCT02722278). The study included a Screening Phase, a Treatment Titration Phase, and a Treatment Maintenance Phase. 

JATENZO was taken orally at a starting dose of 237 mg twice per day with meals. The dose was adjusted on Days 21 and 56 between a minimum of 158 mg twice per day and a maximum of 396 mg twice per day on the basis of the average testosterone concentration obtained over 24 hours post-morning dose. 

The primary endpoint was the percentage of patients with mean plasma total testosterone concentration (Cavg) over 24-hours within the normal eugonadal range on the final PK visit of the study. 

Secondary endpoints were the percentage of patients with a maximum total testosterone concentration (Cmax) above three predetermined limits: less than or equal to 1500 ng/dL, between 1800 and 2500 ng/dL, and greater than 2500 ng/dL. 

One hundred and forty-five (87%) of the 166 hypogonadal men who received JATENZO had a mean total testosterone concentration (Cavg) within the normal eugonadal range at the end of treatment. 

The percentage of patients who received JATENZO and had Cmax less than or equal to 1500 ng/dL, between 1800 and 2500 ng/dL, and greater than 2500 ng/dL at the final PK visit were 83%, 3%, and 3%, respectively. Note that the testosterone concentrations were not measured in serum but the effects of different sample preparation conditions were accounted for in data analysis of the results shown here. The titration scheme for use in clinical practice is based on serum total testosterone [see Dosage and Administration (2.2)].